ebook
Le saviez vous ?
Lisez votre e-book sur ordinateur, tablette et mobile grâce aux applications :
Coups de cœur Cultura
Tous les passeurs de culture peuvent partager leurs découvertes !
Tu as aimé ce produit ? Partage dès maintenant ton coup de coeur :
Three drugs, one decision — and the internet is either a sales pitch or a wall of jargon. The GLP Decision is the version written for the actual decision in front of you: an honest, side-by-side comparison of retatrutide, semaglutide, and tirzepatide.
No book can tell you which one is yours — that's between you and your doctor. This one hands you the real trial data, organized clearly, and a framework to help you choose, or wait, without the hype.
What's inside:
How these drugs actually work — single-, dual-, and triple-receptor agonism, explained plainly
The trial data, side by side — real figures from the named trials, with honest caveats
Side effects and safety, class by class
What's available today — realistic cost, insurance, and timelines
The compounding reality, addressed directly — the risks, with zero how-to and zero sourcing
A real decision framework — built around your urgency, risk tolerance, and access
122 pages, roughly 26,700 words, a focused 2–3 hour read. Every clinical figure checked against the primary sources.
This book is educational and is not medical advice. Retatrutide is an investigational medication in Phase 3 clinical trials and is not FDA-approved. Semaglutide and tirzepatide are FDA-approved prescription medications. Nothing here is a guide to obtaining or starting any medication — those decisions belong to you and a qualified healthcare provider.
